The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19

The Effect of Diabetes Mellitus on the Morbidity and Mortality Rates in Patients With COVID-19

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04591704

Acronym

COVID-19-DM2

Enrollment

2000

Registered

2020-10-19

Start date

2020-03-20

Completion date

2021-07-01

Last updated

2021-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Diabetes Mellitus

Brief summary

All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study. The patients will be divided into two groups, as diabetics and non-diabetics. The COVID-19 patients' medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

Detailed description

All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study. The patients will be divided into two groups, as diabetics and non-diabetics. The diagnosis of diabetes mellitus will be extracted from the medical records and medical history of the patients hospitalised with COVID-19. The COVID-19 patients medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

Interventions

OTHERhospitalisation, necessity of ICU, mortality rate, lung involvement

hospitalisation, necessity of ICU, mortality rate, lung involvement

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

* Patients hospitalized for COVID-19

Exclusion criteria

* Patients with known malignancy * Pregnant patients

Design outcomes

Primary

Measure	Time frame	Description
Duration of Hospitalisation	1 year	The time between admission to hospital and discharge
The need for ICU	1 year	The admission of hospitalized patients to the intensive care unit.
Mortality	1 year	Mortality rates of patients
Lung involvement	1 year	The presence of lung involvement on thorax CT

Countries

Turkey (Türkiye)

Contacts

Primary ContactCevdet Duran

drcduran@gmail.com02762212121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026